Zsírmáj (MASLD/MASH): vizsgálatok itt: Kanada
18 trials · From ClinicalTrials.gov, checked 2026. november 11.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleA Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
- Where
- Edmonton, Hamilton, Montreal, Terrebonne, Toronto, Vaughan
- Életkor
- 18 év to 80 év
- People
- 1650 worldwide
- Run by
- Akero Therapeutics, Inc
See details and how to joinNCT06215716 - 3. fázisTaking peopleLIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
- Where
- Bridgewater, Calgary, Montreal, Québec, Terrebonne, Toronto, Vancouver
- Életkor
- 18 év and over
- People
- 1800 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT06632444 · EU 2024-513739-25-00 - 3. fázisTaking peopleLIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
- Where
- Bridgewater, Calgary, Montreal, Québec, Toronto, Vancouver
- Életkor
- 18 év and over
- People
- 1590 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT06632457 · EU 2024-513741-36-00 - 3. fázisTaking peopleA Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
- Where
- Calgary, London, Ottawa, Toronto, Vancouver, Vaughan, Winnipeg
- Életkor
- 18 év to 80 év
- People
- 1350 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT06318169 · EU 2023-509912-27-00 - 3. fázisTaking peopleA Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
- Where
- Calgary, London, Ottawa, Toronto, Vancouver, Vaughan, Winnipeg
- Életkor
- 18 év to 75 év
- People
- 1800 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT06419374 · EU 2023-510395-31-00 - 2. fázisTaking peopleA Study to Test Whether BI 3802876 is Tolerated in People With Compensated Liver Cirrhosis Due to Metabolic Dysfunction- Associated Steatohepatitis (MASH)
- Where
- Edmonton
- Életkor
- 18 év to 75 év
- People
- 30 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT07325526 - 3. fázisTaking peopleA Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
- Where
- Edmonton, Montreal, Terrebonne, Toronto, Vaughan
- Életkor
- 18 év to 80 év
- People
- 2150 worldwide
- Run by
- Akero Therapeutics, Inc
See details and how to joinNCT06528314 - 3. fázisTaking peopleA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
- Where
- Calgary, Chicoutimi, Edmonton, Halifax, London, North Bay, Québec, Toronto, Trois-Rivières, Vancouver, Winnipeg
- Életkor
- 18 év and over
- People
- 4500 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07165028 · EU 2025-522674-36-00 - No phaseTaking peopleQuantitative Ultrasound Techniques for Diagnosis of Nonalcoholic Steatohepatitis
- Where
- Montreal
- Életkor
- 18 év and over
- People
- 102
- Run by
- Centre hospitalier de l'Université de Montréal (CHUM)
See details and how to joinNCT03572465 - 2. fázisTaking peopleStudy to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH
- Where
- Toronto
- Életkor
- 18 év to 75 év
- People
- 120 worldwide
- Run by
- Madrigal Pharmaceuticals, Inc.
See details and how to joinNCT07335601 - 4. fázisTaking peopleFibrosis Lessens After Metabolic Surgery
- Where
- Montreal
- Életkor
- 18 év to 75 év
- People
- 120 worldwide
- Run by
- The Cleveland Clinic
See details and how to joinNCT06374875 - 3. fázisTaking peopleA Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
- Where
- Québec
- Életkor
- 18 év to 75 év
- People
- 1200 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT07221227 - No phaseTaking peopleStimulating Fat Tissue Storage With Niacin to Reduce Fat Accumulation in the Liver.
- Where
- Sherbrooke
- Életkor
- 20 év to 80 év
- People
- 36
- Run by
- Université de Sherbrooke
See details and how to joinNCT06843148 - No phaseTaking peoplePreoperative Ketogenic Diet for Reduction of Hepatic Steatosis
- Where
- London
- Életkor
- 18 év and over
- People
- 124
- Run by
- Anton Skaro
See details and how to joinNCT05884723 - 1. fázisTaking peopleA Phase 1b Study of QX1206 in T2DM Patients With NAFLD
- Where
- Toronto
- Életkor
- 18 év to 64 év
- People
- 52
- Run by
- 1Globe Health Institute
See details and how to joinNCT06694935 - No phaseNot yet taking people in KanadaCharacterization and Management of Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)
- Where
- Québec
- Életkor
- 18 év and over
- People
- 120
- Run by
- Institut universitaire de cardiologie et de pneumologie de Québec, University Laval
See details and how to joinNCT06764056 - No phaseTaking peopleEffects of TOTUM-448 on Liver Fat Content, Cardiometabolic Risk Factors and Gut Microbiota Among Participants with MASLD
- Where
- Québec
- Életkor
- 18 év to 75 év
- People
- 70
- Run by
- Valbiotis
See details and how to joinNCT06704321 - 2. fázisTaking peopleSoluble Fibre Supplementation in NAFLD
- Where
- Hamilton
- Életkor
- 8 év to 17 év
- People
- 60
- Run by
- McMaster University
See details and how to joinNCT05480696